To expand the range of sarcomas examined, we conducted a pilot study on the targeting of β-ARs with propranolol in an SFT patient and in patient-derived cells, further confirming the functional role of β-ARs in the proliferation and chemoresistance of sarcomas. The gene discussed is CTBP1; the disease is sarcoma.